Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agomelatine is an atypical antidepressant medication primarily indicated for the treatment of major depressive disorder (MDD). Developed by Servier and marketed as a generic by Standpharm under the name Agorid, it possesses a unique pharmacological profile as a potent agonist at melatonin MT1 and MT2 receptors and a selective antagonist at serotonin 5-HT2C receptors. By targeting these receptors, agomelatine helps to resynchronize disrupted circadian rhythms, which are a hallmark of clinical depression. It is noted for its lack of significant effect on serotonin levels, which contributes to a lower incidence of common antidepressant side effects such as sexual dysfunction and weight gain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agomelatine (Standpharm).